Vs. tirzepatide

Retatrutide vs tirzepatide: what does the research show?

The two compounds were studied in separate programmes. Retatrutide research investigates GLP-1R/GIPR/GCGR agonism; tirzepatide literature describes GIPR/GLP-1R agonism. In their respective obesity trials investigators reported a mean change from baseline in body weight of −24.2% at week 48 (retatrutide Phase 2, NEJM 2023) and −28.3% at week 80 (retatrutide Phase 3 TRIUMPH-1), against −20.9% at week 72 (tirzepatide SURMOUNT-1, NEJM 2022). No head-to-head trial of these two compounds has been published, so the figures are descriptive cross-trial observations and the study designs do not support treating them as a comparison.

Retatrutide vs tirzepatide at a glance

Attribute Retatrutide Tirzepatide Compound class Triple GLP-1 / GIP / glucagon receptor agonist Dual GIP / GLP-1 receptor agonist (imbalanced agonism) Pivotal Phase 3 result 28.3% mean weight reduction at 80 weeks, 12 mg (TRIUMPH-1, 2025) 20.9% mean weight reduction at 72 weeks, 15 mg (SURMOUNT-1, NEJM 2022) Half-life ~6 days ~5 days (116.7 h mean) Evidence tier Tier 1 (human RCT) Tier 1 (human RCT) Reference-drug regulatory status Investigational — not approved as a medicine in any jurisdiction Reference drug (Mounjaro/Zepbound) is FDA-approved; the research-grade material supplied for laboratory use is unapproved and is not the finished pharmaceutical

Cross-trial descriptive comparison from separate clinical programmes, not a head-to-head trial result. Figures describe the reference-drug clinical literature, not a claim about the research-grade material.

Why the extra receptor matters

Tirzepatide pharmacology reports full agonist potency at GIPR and cAMP-biased signalling at GLP-1R. Retatrutide research adds a third characterised receptor, GCGR, whose hepatic energy-expenditure endpoints are investigated alongside the incretin endpoints both compounds share via GLP-1R and GIPR.

Frequently asked questions

How is retatrutide different from tirzepatide or semaglutide in the literature?

By characterised receptor coverage: semaglutide literature describes GLP-1R agonism, tirzepatide literature describes GIPR/GLP-1R agonism, and retatrutide research investigates GLP-1R/GIPR/GCGR agonism. The GCGR arm is the one specific to retatrutide, and hepatic endpoints are investigated in relation to it.

Tirzepatide vs retatrutide — what is the difference?

Tirzepatide is characterised as a dual GIPR/GLP-1R agonist; retatrutide research investigates a third receptor, GCGR, in addition to those two. Their obesity programmes were conducted separately and no head-to-head trial has been published, so results from one programme are not a comparison with the other. Retatrutide also remains investigational, while tirzepatide is approved as a medicine in some jurisdictions under other manufacturers’ brand names.

Certificates of Analysis for released batches are published on the website. Browse the lab-verified catalogue — research use only.

References

Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. N Engl J Med (2023)

Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med (2022)

TRIUMPH-1 pivotal Phase 3 trial. ClinicalTrials.gov (NCT05929066)

Related research

Retatrutide mechanism this hub

Retatrutide research & evidence this hub

Full side-by-side comparison table

Retatrutide product page

Tirzepatide product page

This site is an official property of New-U Research Compounds, operated by Hilxera Distribution Services LLC (registration publicly checkable). Every order, account and payment completes on the canonical store at new-u.io — verify any New-U domain against the official domains list.

All compounds referenced are supplied for laboratory research use only and are not for human or veterinary use. Nothing on this page is medical advice.

Research use only — not for human consumption. All products are supplied strictly for laboratory research purposes.